SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a community-driven token focused on cannabis culture and natural wellness. Discussions highlight its mission to challenge the pharmaceutical industry and promote the plant's benefits. The community emphasizes its organic growth, freedom, and aim to bring balance to the digital world.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital ($APLD) is trending after its earnings call, where the company highlighted substantial revenue growth and potential new hyperscaler partnerships, fueling optimism about its future in AI data centers. The community is buzzing about potential price target upgrades and the possibility of a short squeeze, while some traders are closely monitoring overnight trading activity and potential profit-taking strategies. Despite discussions around debt and valuation, the overall sentiment leans bullish, driven by the company's expansion plans and its position in the growing AI sector.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the community anticipates a potential ETF and discusses key resistance levels that need to be broken for a significant upward move. Some traders are pointing to technical formations suggesting a possible breakout, while others express concerns about LTC's historical underperformance compared to other cryptocurrencies. The conversation also includes speculation on how the broader market and potential government shutdowns could impact Litecoin's price.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a new strategic partnership to develop quantum-resistant chips for U.S. defense applications, sparking excitement about potential government contracts. Community members are actively discussing the company's growth potential and comparing it to other quantum computing stocks. Some investors believe LAES is significantly undervalued and poised for a substantial run.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to renewed interest in privacy coins and speculation around potential use cases amidst growing concerns about financial surveillance; the community is actively discussing price targets and the cryptocurrency's long-term potential, drawing comparisons to Bitcoin's fundamentals and previous market cycles. Bullish sentiment seems to be building around ZEC's privacy features and fixed supply, with some believing it could reach new all-time highs if the current movement continues.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending as the community discusses its potential for a breakout, citing its low token supply and undervalued status relative to Total Value Locked (TVL). Some investors express frustration with its lagging performance compared to other cryptocurrencies, while others point to upcoming catalysts and governance updates as potential drivers for future growth. Bullish sentiment revolves around its strong fundamentals and the expectation of a significant upward move.

Spell Token

Spell Token is gaining attention, with community members actively discussing potential catalysts and expressing hopes for a significant price surge. Some are focused on accumulating more tokens, while others are sharing long-term price predictions and potential targets. Discussions also include the possibility of new developments and partnerships.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to increased community discussion around its potential short squeeze and transition into AI/HPC data centers, with some traders comparing it to peers like APLD and IREN. The community highlights TeraWulf's attractive entry point, high short interest, and backing from Google, fueling speculation about significant upward movement. Chatter suggests that TeraWulf is playing catch up with other tickers in the AI/HPC sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as community members discuss its potential as a rare earth play and its unique position as a North American antimony processor amid increasing demand and supply constraints from China. Recent insider buying and a large government contract are also fueling optimism, with some speculating about a potential government stake. Community members express bullish sentiment and discuss price targets.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. ($INOD) is trending due to bullish technical analysis and anticipation surrounding the upcoming Gen AI Summit and Q3 earnings report. The community is actively discussing potential new contracts or a possible acquisition, fueled by recent institutional buying and a lack of insider selling. Many see $INOD as undervalued in the growing AI data market, with some speculating about significant long-term growth and potential takeover targets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Equity

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.


Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth

Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results...

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...

Enanta Pharmaceuticals to Appeal Ruling Related to 953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United...

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline...

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will...

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$11.46
Prev Close	$11.30
Open	$11.40
Dividend Yield	0.00%
50-Day Moving Average	$8.55
Beta	1.05
Avg. Volume	1.18M
PE Ratio	-2.61

52-Week High	$15.34
52-Week Low	$4.09
Market Capitalization	$326.04M
EPS (Annual)	-$5.49
Price to Book	3.05
Revenue Per Employee	$516,297.71
Enterprise Value/EBITDA	N/A

ENTA
Enanta Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ENTA News

ENTAEnanta Pharmaceuticals Inc